HOPKINTON, Mass., Feb. 18 /PRNewswire/ -- Aderis Pharmaceuticals announced today that Dr. William Wheeler, Vice President and Chief Medical Officer of Aderis Pharmaceuticals, will serve as a panelist in a Focus Session titled "Biotech's Solutions to Alzheimer's and Parkinson's Disease." The event will take place on Wednesday, February 23, 2005 at 9:30 a.m. EST during the BIO CEO & Investor Conference 2005. The conference will run February 23-24 at the Waldorf-Astoria in New York City.
The panel will provide a clinical perspective on the problems and opportunities that are being explored in search of a cure for Alzheimer's and/or Parkinson's disease. Aderis' partner, Schwarz Pharma, recently resubmitted a New Drug Application with the FDA and an MAA with the EMEA for Neupro(R) rotigotine transdermal system, the first once daily transdermal patch to treat Parkinson's Disease.
This panel presentation is being webcast live by Thomson/CCBN from the Waldorf=Astoria Hotel in New York City and may be accessed through the following link: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=28873&item_id=1009743 or from the company's website at http://www.aderis.com/.
About Aderis Pharmaceuticals
Aderis Pharmaceuticals is a private biopharmaceutical company engaged in small molecule drug development to treat central nervous system, cardiovascular and inflammatory disorders. The Company currently has four product candidates in eight internal or partnered clinical development programs. Aderis Pharmaceuticals has a strategic alliance with Schwarz Pharma AG, for the development of Neupro(R) rotigotine transdermal system, a proprietary dopamine agonist formulated as a once daily, continuous delivery, transdermal patch. NDA and MAA applications have been filed for Neupro(R) in Early Stage Parkinson's disease. There are ongoing Phase III studies of the patch in Advanced Parkinson's disease and they have completed Phase I studies of a nasal spray formulation for acute Parkinson's as well as a Phase IIb study of the patch for the treatment of Restless Legs Syndrome. The Company also has a corporate collaboration with King Pharmaceuticals for development of its adenosine A2A agonists. Aderis Pharmaceuticals' product pipeline also includes small molecule, receptor agonists and antagonists for the treatment of diabetic foot ulcers, the diagnosis and prognosis of coronary artery disease, hair growth, edema, rheumatoid arthritis and other cardiovascular and renal indications. Founded in 1994, Aderis Pharmaceuticals is headquartered in Hopkinton, Massachusetts and has research facilities in Richmond, Virginia.
Certain statements in this news release that are not historical fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results of Aderis Pharmaceuticals to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Such statements include, but are not limited to, any statements relating to the Company's development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties, including but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates; unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization; the uncertainty of patent protection for the Company's intellectual property or trade secrets; and the Company's ability to obtain additional financing if necessary. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, some but not all of which may have been mentioned above.
Neupro is a registered trademark of Schwarz Pharma AG.
508-497-2300 ext. 224
The Ruth Group
CONTACT: Sharon Correia, Aderis Pharmaceuticals, +1-508-497-2300,ext. 224, firstname.lastname@example.org; Janine McCargo, The Ruth Group,+1-646-536-7033, email@example.com, for Aderis Pharmaceuticals